Skip to main content

Market Overview

Biogen Inc. Retreats From High After FDA Approval Of Spinraza

Share:
Biogen Inc. Retreats From High After FDA Approval Of Spinraza

Biogen Inc (NASDAQ: BIIB) shares are trading higher by $4.30 at $291.83 in Tuesday's session. The catalyst for the rally is the announcement that the FDA has approved Spinraza to treat spinal muscular atrophy. Its partner for the drug, Ionis Pharmaceuticals Inc (NASDAQ: IONS) is also in the green by $1.74 at $55.15.

After a higher open, Biogen continued in that direction until it peaked at $296.38 at 10:10 a.m. EST. That marked the highest level for the issue since it peaked on December 9 at $306.98. Since reaching that level, it has been drifting lower and has continued to make new lows for the session.

In order to fill the void in price action from Friday's session, the issue would need to fall to $288.38.

 

Related Articles (BIIB + IONS)

View Comments and Join the Discussion!

Posted-In: Biotech News Technicals FDA Intraday Update Movers Trading Ideas General

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com